2015
DOI: 10.1158/2326-6066.cir-15-0035
|View full text |Cite
|
Sign up to set email alerts
|

Ipilimumab-Induced Encephalopathy with a Reversible Splenial Lesion

Abstract: Ipilimumab, an anticytotoxic T-lymphocyte antigen (CTLA)-4 monoclonal antibody, is a first-line therapy for stage IV melanoma. Although high-grade immune-related adverse events occur in 25% of patients receiving ipilimumab, serious neurologic toxicity, primarily consisting of transient sensory and motor neuropathies, affects less than 1% of patients. We present a case report of a patient with melanoma who received highdose ipilimumab at 10 mg/kg as first-line therapy for metastatic disease. After the third dos… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
41
0
5

Year Published

2015
2015
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 62 publications
(47 citation statements)
references
References 16 publications
1
41
0
5
Order By: Relevance
“…Orbital myositis and encephalopathy with arthralgias were also described in case reports, as shown in Table .…”
Section: Resultsmentioning
confidence: 94%
“…Orbital myositis and encephalopathy with arthralgias were also described in case reports, as shown in Table .…”
Section: Resultsmentioning
confidence: 94%
“…We report the case of a 60-year-old man who succumbed to progressive and subacute CNS demyelination that developed while he was receiving nivolumab following ipilimumab for metastatic melanoma. CNS demyelination has never been reported as a side effect of anti-PD-1 therapy, although a case of encephalopathy with a reversible splenial lesion was described in association with ipilimumab treatment (2). As the use of these agents increases, it is important to be aware of this rare but severe potential complication.…”
Section: Introductionmentioning
confidence: 99%
“…Ipilimumab-associated neurological irAEs span diverse entities including severe meningo-radiculo-neuritis [18], reversible splenial lesions [19, 20], hypophysitis [21], meningitis [21], acute cerebellitis [22], Guillain-Barre syndrome [21, 23], myasthenia gravis [2427], bilateral phrenic nerve paralysis [28], Bell’s palsy [28], chronic inflammatory demyelinating polyneuropathy (CIDP) [29], transverse myelitis [29], encephalitis [30], necrotic myelopathy [31], and partial motor convulsive status (epilepsia partialis continua) [32]. Herein, we report two cases of ipilimumab-associated neurological irAEs manifesting as meningoencephalomyelitis and AIDP respectively.…”
Section: Discussionmentioning
confidence: 99%